Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Palatin technologies, inc. exchanges : Amex save search
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published: 2024-02-28 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -44.58%
H: 25.45%
C: 11.36%
pl9643 disease eye trial results
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Published: 2024-02-15 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -2.66%
H: 0.25%
C: -21.84%
year update financial results
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Published: 2024-02-09 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 1.24%
H: 4.42%
C: 4.42%
report year
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.53%
H: 15.53%
C: 7.11%
pl9643 disease eye trial
Palatin Announces Closing of $10 Million Registered Direct Offering
Published: 2024-02-01 (Crawled : 21:00) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 8.03%
H: 0.0%
C: -3.08%
million direct offering
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Published: 2024-01-08 (Crawled : 15:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 1.82%
H: 11.43%
C: 10.71%
year update
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Published: 2024-01-03 (Crawled : 18:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.0%
H: 1.04%
C: -10.62%
vyleesi pharmaceuticals
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Published: 2023-12-20 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -4.96%
H: 17.83%
C: 7.39%
vyleesi pharmaceuticals
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Published: 2023-11-14 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -2.99%
H: 2.56%
C: -1.54%
year update financial results
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Published: 2023-11-09 (Crawled : 12:30) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.0%
H: 2.5%
C: -4.0%
report year
Palatin Announces Closing of $5 Million Registered Direct Offering
Published: 2023-10-24 (Crawled : 21:00) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.0%
H: 4.95%
C: -3.38%
direct offering
Palatin Announces $5 Million Registered Direct Offering
Published: 2023-10-23 (Crawled : 13:30) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -17.08%
H: 8.86%
C: 4.02%
direct offering
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 1.16%
H: 33.71%
C: 21.14%
vyleesi results
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Published: 2023-10-18 (Crawled : 20:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -3.41%
H: 5.79%
C: 1.76%
agonist positive preclinical study
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Published: 2023-10-16 (Crawled : 20:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.58%
H: 5.75%
C: 0.57%
pl8177 conference treatment week
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
Published: 2023-09-22 (Crawled : 20:00) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
| Email alert
Add to watchlist
report year
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
Published: 2023-09-07 (Crawled : 22:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 0.43%
H: 3.49%
C: -2.18%
pl9643 disease treatment eye study
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-07 (Crawled : 20:00) - prnewswire.com
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: -6.31%
conference global
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: -0.34%
H: 2.86%
C: -5.17%
treatment program
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
Published: 2023-08-08 (Crawled : 12:00) - biospace.com/
PTN | $1.75 1.74% 0.0% 140K
|
Health Technology
|
| O: 14.68%
H: 11.9%
C: 5.6%
vyleesi pharma pharmaceuticals commercial china study
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.